Anzeige
❌
Mehr »
Sonntag, 22.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GT

WKN: A3EE5F | ISIN: US4037831033 | Ticker: L9S
Frankfurt
20.11.26 | 08:00
4,080 Euro
+3,03 % +0,120
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GYRE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GYRE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,8203,88021.11.
3,8203,88020.11.

Aktuelle News zur GYRE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.11.GYRE THERAPEUTICS, INC. - 10-Q, Quarterly Report-
05.11.Gyre Therapeutics Inc.: Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates1
22.10.GYRE THERAPEUTICS, INC. - 8-K, Current Report1
16.09.Gyre Therapeutics auf Morgan Stanley Konferenz: Cashflow finanziert Pipeline1
26.08.GYRE THERAPEUTICS, INC. - 8-K, Current Report1
07.08.GYRE THERAPEUTICS, INC. - 10-Q, Quarterly Report1
07.08.GYRE THERAPEUTICS, INC. - 8-K, Current Report3
GYRE THERAPEUTICS Aktie jetzt für 0€ handeln
07.08.Gyre Therapeutics GAAP EPS of -$0.12 misses by $0.06, revenue of $29.1M beats by $2.61M1
07.08.Gyre Therapeutics Inc.: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update1.381Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by...
► Artikel lesen
16.07.GYRE THERAPEUTICS, INC. - 8-K, Current Report1
16.07.Gyre Therapeutics appoints three directors to board1
16.07.Gyre Therapeutics Inc.: Gyre Therapeutics Appoints Three New Members to its Board of Directors5
16.06.GYRE THERAPEUTICS, INC. - 8-K, Current Report1
10.06.GYRE THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans-
02.06.GYRE THERAPEUTICS, INC. - 8-K, Current Report3
07.05.Gyre Therapeutics Inc.: Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update491Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted...
► Artikel lesen
04.05.Gyre Therapeutics Inc.: Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company372Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory...
► Artikel lesen
12.03.Gyre Therapeutics Inc.: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update340Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1